top of page
Scientist on Computer_edited_edited

Scientist on Computer_edited_edited

Conference

Conference

Add a Title

Add a Title

icon_PrIMAVeRA_crop

icon_PrIMAVeRA_crop

Laboratory

Laboratory

Drug and Syringe

Drug and Syringe

Girl at the Pediatrician

Girl at the Pediatrician

Pipetting Samples

Pipetting Samples

hand shake_Inno4Vac KoM_Source Wix

hand shake_Inno4Vac KoM_Source Wix

Add a Title

Add a Title

Preventive services

Preventive services

Add a Title

Add a Title

PrIMAVeRa

In-silico tools to evaluate the effect of vaccines on reduction of AMR

logo - cropped.png

‘PrIMAVeRa’ means ‘Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance’.

It is a European project funded by the Innovative Medicines Initiative 2 (IMI2) with the goal of developing an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes). This platform will aim to enable policymakers to reach data-driven decisions regarding the prioritisation of specific vaccines and monoclonal antibodies (mAbs), informing the strategic allocation of limited resources.

A project sustainability plan will also be designed by the project partners with the goal of providing long-term access to the project results, including the models, once the project has finished.

PRIMAVERA is part of the AMR Accelerator Programme.

Primavera flyer for web_3x.jpg

Contact

For PrIMAVeRa inquiries, please contact: 

European Vaccine
Initiative (EVI)

Coordination

Project Leader: Irina Meln

irina.meln@euvaccine.eu 

 

UniversitätsKlinikum Heidelberg  

Voßstraße 2, Geb. 4040  

69115 Heidelberg, Germany 

 

www.euvaccine.eu

Join European Vaccine Initiative mailing list to stay up to date with the PrIMAVeRa project updates:

Thanks for submitting! You can unsubscribe at anytime.

bottom of page